Net Product Revenue was Organogenesis Holdings’s largest product and service line in fiscal 2025, bringing in $563.03M of $564.17M (100%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Product Revenue | — | $433.14M | $482.04M | $563.03M | ||||||
| Advanced Wound Care | $422.23M | — | — | — | ||||||
| Surgical & Sports Medicine | $28.66M | — | — | — | ||||||
| Grant Income | — | — | — | $1.14M | ||||||
| Total | $450.89M | $433.14M | $482.04M | $564.17M |
Organogenesis Holdings brought in $564.17M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Organogenesis Holdings regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $482.04M. Net Product Revenue was the largest at $563.03M (99.8%), ahead of Grant Income at $1.14M (0.2%).
Organogenesis Holdings began breaking out Net Product Revenue in fiscal 2023 and Grant Income in fiscal 2025. Organogenesis Holdings stopped reporting Advanced Wound Care ($422.23M in fiscal 2022) and Surgical & Sports Medicine ($28.66M in fiscal 2022) as separate lines.
Advanced Wound Care was Organogenesis Holdings’s largest revenue line in fiscal 2025, bringing in $531.24M of $563.03M (94%).
| Customer | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Advanced Wound Care | $405.51M | $453.64M | $531.24M |
| Surgical & Sports Medicine | $27.63M | $28.40M | $31.79M |
| Total | $433.14M | $482.04M | $563.03M |
Organogenesis Holdings brought in $563.03M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 16.8% from $482.04M in fiscal 2024. Advanced Wound Care was the largest at $531.24M (94.4%), ahead of Surgical & Sports Medicine at $31.79M (5.6%).
Compared with fiscal 2024, Advanced Wound Care grew 17.1% to $531.24M and Surgical & Sports Medicine grew 11.9% to $31.79M. From fiscal 2023 to 2025, combined revenue from these revenue lines grew from $433.14M to $563.03M, a compound annual growth rate of 14.0%. Advanced Wound Care's share of the total rose from 93.6% to 94.4%.
Organogenesis Holdings (ORGO) reports its revenue by product and service and by customer. In fiscal 2025, Net Product Revenue was its largest product and service line, bringing in $563.03M (99.8% of the total), followed by Grant Income at $1.14M (0.2%).
Net Product Revenue was Organogenesis Holdings' largest product and service line in fiscal 2025, bringing in $563.03M, or 99.8% of the $564.17M total across its two product and service lines.
Advanced Wound Care was Organogenesis Holdings' largest revenue line in fiscal 2025, bringing in $531.24M, or 94.4% of the $563.03M total across its two revenue lines.
Advanced Wound Care grew faster than Surgical & Sports Medicine in fiscal 2025, up 17.1% from $453.64M to $531.24M. Surgical & Sports Medicine grew 11.9% to $31.79M.
Every figure comes from Organogenesis Holdings' annual financial filings, as reported. Each line keeps the name Organogenesis Holdings gives it, and years follow its fiscal calendar.
Organogenesis Holdings' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.